Aflibercept is a recombinant fusion protein acting as a decoy receptor for VEGF, used to treat wet age-related macular degeneration and metastatic colorectal cancer. It binds VEGF-A, VEGF-B, and PlGF, inhibiting angiogenesis. It is grouped under the following drug class(es): Biologics and VEGF inhibitors. Its therapeutic use is listed as ophthalmic agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include VEGF Trap-Eye, VEGF Trap – regeneron and afliberceptum. Its PubChem SID is 481101479.
Aflibercept
| CAS No | 862111-32-8 |
|---|---|
| Molecular Formula | C4318H6788N1164O1304S32 |
| Molecular Weight | 115 kDa |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Aflibercept is a recombinant fusion protein acting as a decoy receptor for VEGF, used to treat wet age-related macular degeneration and metastatic colorectal cancer.
The listed CAS number is 862111-32-8.
The listed molecular formula is C4318H6788N1164O1304S32.
The listed molecular weight is 115 kDa.
N/A.
The source lists VEGF Trap-Eye, VEGF Trap - regeneron and afliberceptum.